Incannex has received approval from Bellberry Human Research Ethic Committee (‘HREC’) to commence the bioequivalence/bioavailability (‘BA/BE’) clinical trial to asses the pharmacokinetics and tolerability of IHL-42X.
Cannabis stock Bod Australia (ASX:BDA) has entered the fight against what is known as “long-COVID”. What is ‘long-COVID’? “Long-COVID” ... Read More The post 1 in 10 COVID survivors in Britain still suffer symptoms; ASX cannabis stock Bod wants to help appeared first on Stockhead.
Got 90 seconds? Then listen to Director, Peter Widdows tell us about their company news. Medicinal cannabis and psychedelic therapies ... Read More The post 90 Seconds With…..Peter Widdows, Incannex (ASX:IHL) appeared first on Stockhead.
Special Report: The June quarter demonstrated IHL’s ability to execute on a multi-channel development strategy. ... Read More The post A busy Q4 shows how Incannex Healthcare is laying the foundations for its clinically backed global growth strategy appeared first on Stockhead.